Navigation Links
Omeros Corporation Reports Third Quarter 2013 Financial Results
Date:11/7/2013

er 30, 2013, total (i.e., cash and non-cash) operating expenses, excluding the litigation expense, increased by $3.1 million compared to the same period in 2012. The increase was primarily due to the non-cash rent and stock-based compensation expenses of $3.2 million in 3Q 2013 compared to $576,000 in 3Q 2012. The remaining increases were related to conducting the company's Phase 1 clinical program evaluating OMS824, advancing our MASP-2 program, preparing the New Drug Application (NDA) and Marketing Authorization Application (MAA) for OMS302, planning for the commercial launch of OMS302 in the second half of 2014, and non-recurring legal expenses incurred in connection with the CCIC matter. These higher costs were partially offset by lower overall clinical trial expenses related to the completion of the company's OMS302 Phase 3 clinical program in January 2013 and the completion of the company's first OMS103HP Phase 3 clinical trial in arthroscopic partial meniscectomy patients in December 2012.

Total revenue for the quarter ended September 30, 2013 was $196,000 compared to $1.4 million for the same period in 2012. This decrease was primarily due to lower revenue recognized from the company's GPCR platform development funding agreement with Vulcan Inc. and its affiliate. While research continues under the company's GPCR program, no additional deferred revenue under the Vulcan agreement remains to be recognized after the first quarter of 2013.

For the quarter ended September 30, 2013, Omeros reported a net loss of $13.9 million, or $0.46 per share, inclusive of the above-referenced $3.2 million of non-cash charges equaling $0.11 per share, compared to a net loss of $13.3 million, or $0.51 per share, inclusive of the above-referenced $576,000 of non-cash charges equaling $0.02 per share, for the same period in 2012.

At September 30, 2013, Omeros had cash, cash equivalents and short-term investments of $9.0 million. On October 24, 2013, subseque
'/>"/>

SOURCE Omeros Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Omeros Announces Closing of $16.2 Million Registered Direct Offering of Common Stock
2. Omeros to Present at the 12th Annual Needham Healthcare Conference
3. Omeros Corporation Reports Fourth Quarter and Year-End 2012 Financial Results
4. Omeros Announces Enrollment in Phase 1 Clinical Trial Evaluating OMS824
5. Omeros to Present at the 19th Annual Newsmakers in the Biotech Industry Conference
6. Omeros Has Now Unlocked Over Half of the Class A Orphan GPCRs
7. Omeros Announces it has Unlocked 30 Percent of Class A Orphan GPCRs
8. Omeros Announces It Has Unlocked Over 20 Percent of Class A Orphan GPCRs
9. China Cord Blood Corporation to Report Second Quarter and First Half of Fiscal 2014 Financial Results
10. Attention Amarin Corporation plc Investors: Amarin Corporation plc Misled Investors According to a Newly Filed Class Action
11. General Patent Corporation Chairman and CEO Alexander Poltorak Joins Spherix Board Industry veteran and authority on patent law and valuation joins Spherix as director
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2015)... May 26, 2015 /PRNewswire/ - Fluorinov Pharma (Fluorinov), a ... Luke M. Beshar to its Board of Directors. ... pharmaceutical industry expertise as Fluorinov accelerates its clinical development ... team, it is a pleasure to welcome Luke to ... impact on the strategy, financial strength and success of ...
(Date:5/26/2015)... 26, 2015 Just the characterization of ... unmet biomedical need does not guarantee immediate acceptance. ... has seen many prior failures is often met with ... use is an irony that is often an unappreciated ... start-up company, Asymmetrex has found that building ...
(Date:5/25/2015)... Phenome Networks, a software-as-a-service plant ... availability, beginning May 31st, of its next-generation Phenome One ... solidifies Phenome Networks’ lead in the plant breeding market, ... intuitive breeding workflow based on years of experience with ... design, and more. The new version of Phenome One, ...
(Date:5/22/2015)... 2015 Knowledgent , the data ... explores the potential of big data analytics in the ... developed to help life sciences and healthcare organizations understand ... gain critical business insights. , The life sciences and ... driven by patient profiling, compliance and regulatory requirements, and ...
Breaking Biology Technology:Luke M. Beshar Appointed to Fluorinov Pharma Board of Directors 2Luke M. Beshar Appointed to Fluorinov Pharma Board of Directors 3In August Asymmetrex Will Present Details of Its Crowdsourcing Campaign to Determine the Extent of Application of New Technologies for Counting Adult Tissue Stem Cells 2In August Asymmetrex Will Present Details of Its Crowdsourcing Campaign to Determine the Extent of Application of New Technologies for Counting Adult Tissue Stem Cells 3Phenome Networks Announces its Next Generation Plant Breeding Management and Analytics Software 2Phenome Networks Announces its Next Generation Plant Breeding Management and Analytics Software 3New White Paper Explores the Potential of Big Data Analytics in Life Sciences and Healthcare 2
... ... release of a suite of four STR kit configurations designed to fulfill latest ... detect the European Standard Set and other routinely tested loci, plus the five ... types, favored by alpha test labs, and enables easier database sharing and standardization. ...
... ... , ... 1, 2009 -- Artemis Health Institute has entered into a partnership with New York-based Memorial ... will focus on three core areas -- clinical care, research and training. , , , ...
... , National Institute of Mental Health awards $4.5 ... , BOSTON, Sept. 30 Children,s ... has been awarded a Grand Opportunity grant from the National ... package, to pursue "whole-genome" sequencing of patients with autism, using ...
Cached Biology Technology:New STR Systems from Promega Comply with Latest DNA Database Standards 2Memorial Sloan-Kettering Selects Artemis as Affiliate for India 2Memorial Sloan-Kettering Selects Artemis as Affiliate for India 3Stimulus Grant To Fund 'Whole-Genome Sequencing' In Children With Autism 2Stimulus Grant To Fund 'Whole-Genome Sequencing' In Children With Autism 3Stimulus Grant To Fund 'Whole-Genome Sequencing' In Children With Autism 4
(Date:4/10/2015)... Research and Markets ( http://www.researchandmarkets.com/research/cjk4gb/security ) has ... - NEC" report to their offering. ... to supply a range of IT security management and ... on the development of a Big Data and cloud ... Asia-Pacific region is a core ...
(Date:4/8/2015)... 2015  Infinisource, a leading provider of SaaS-based Human ... a leading supplier of biometric identification and security ... most advanced biometrically-enabled time clock, the companies announced ... is setting a bold, new standard for the ... small and mid-size employer. When connected to the ...
(Date:4/2/2015)... HAMBURG, Germany , April 2, 2015 /PRNewswire/ ... ten fingerprint tests DERMALOG by far outperforms the ... While always maintaining high accuracy, the system is ... second. Hence, the speed proves up to be ... 40% faster than its runner-up performance. ...
Breaking Biology News(10 mins):NEC Security Competitive Profile 2015 2iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 2iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 3DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 2DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 3
... of UPMC have identified a potential target for ... the most prevalent sexually transmitted bacterial infection in ... Darville, MD, chief of the Division of Pediatric ... of Chlamydia that, when investigated in an animal ...
... peanut-butter mixture given at home is successfully promoting recovery ... to a group of researchers at Washington University School ... percent of all Malawian children with an estimated 13 ... of five. , Mark J. Manary, M.D., professor of ...
... Boston, MA--Boston University School of Medicine (BUSM) will present The ... September 14, 2007 at noon. The annual lecture is in ... researcher in BUSMs Pulmonary Center. Kim Hanson, along with ... 175, the second plane that struck the World Trade Center ...
Cached Biology News:Study by Pittsburgh researchers identifies possible vaccine target for chlamydia 2Thousands of starving children could be restored to health with peanut butter program 2Thousands of starving children could be restored to health with peanut butter program 3Lecture to honor victim of Sept. 11 tragedy 2
Collected from animals that are 16 to 18 months old. Sterile, Cell culture tested, ID clarifier: USA Origin...
This device is designed to run four simultaneous separations with the following StemSep ; column sizes: 0.3in., 0.5in., and 0.6in.. Depending on the column size, a range of 2x10 7 - 1.5 x 10 9 cell...
Contact us for more information...
... 20-HETE is a cytochrome P450 (CYP450) metabolite ... the renal and cerebral vasculature. In rat ... mediates pressure-induced autoregulatory vasoconstriction. 20-HETE is excreted ... of free 20-HETE (20-40 pg/ml in human ...
Biology Products: